Sedana Medical AB (publ) (SEDANA) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to today's webcast with Stana Medical, where CEO Johannes Doll, CFO Johan Spets and CMO Peter Säcke will present the report for the first quarter of 2025. After the presentation, there will be a Q&A, so if you're calling in and want to ask a question, please press star 9 to raise your hand and then star 6 to unmute yourself when handed the word. You can also send in questions via the form to the right. And with that said, I hand over the word to you guys. Thank you. Welcome to our Q1 report 2025. Thank you very much for joining us today. Let's jump straight into the highlights on page three. It's a quarterly report that I'm very happy with as we have made strong progress across all of our three priorities. On the top line, we have come out of the gate strong with a new record in quarterly sales of 57.5 million SEC, which is the first quarter ever above 50 million SEC and a year-over-year growth of 18%. 15% of that is organic. The rest is contract manufacturing revenue from our newly acquired manufacturing plant in Malaysia. What's behind the growth is a good quarter in Germany with 8% growth and continued very strong performance in our other direct markets outside Germany with 50% growth. What's also worth mentioning here is that the publication of the CESAR study on March 18th has not affected our growth trajectory. That is true for March, as you can see in the numbers in this report. And I can also confirm that is true for April as well, which you cannot see in this report. We are tracking daily orders and also all conversations our field force has with customers about CESAR. And as I said, do not see a change in our growth trajectory. Dice progress also on the profitability side. Gross margins are stable at 71%. In the second half of the year, we...